申请人:Abbott Laboratories
公开号:US05140018A1
公开(公告)日:1992-08-18
Novel 1,3,2-benzodithiazole-1-oxides of formula (I) ##STR1## and their pharmaceutically acceptable salts are disclosed, wherein R.sup.1 is a substituent on the 4-, 5-, 6- or 7-position of the benzodithiazole nucleus selected from the group consisting of hydrogen, (C.sub.1 -C.sub.4)alkyl, halogen, halo(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, and nitro; and R.sup.2 is selected from the group consisting of (C.sub.1 -C.sub.12)alkyl; substituted (C.sub.1 -C.sub.12)alkyl; (C.sub.2 -C.sub.16)alkenyl; (C.sub.2 -C.sub.16)alkynyl; (C.sub.3 -C.sub.10)cycloalkyl; (C.sub.6 -C.sub.10)aryl; mono- or di-substituted (C.sub.6 -C.sub.10)aryl; (C.sub.6 -C.sub.10)aryl-(C.sub.1 -C.sub.4)alkyl; mono- or di-substituted (C.sub.6 -C.sub.10)aryl-(C.sub.1 -C.sub.4)alkyl; heterocycle-(C.sub.1 -C.sub.4)alkyl; and mono- or di-substituted heterocycle-(C.sub.1 -C.sub.4)alkyl. Also disclosed are the antifungal use and method of preparation of such compounds, as well as their formulation as pharmaceutical compositions.
本发明涉及一种式为(I)的1,3,2-苯并二噻唑-1-氧化物及其药学上可接受的盐,其中R1是选自氢、(C1-C4)烷基、卤素、卤代(C1-C4)烷基、(C1-C4)烷氧基和硝基的苯并二噻唑核的4-、5-、6-或7-位取代基;R2选自(C1-C12)烷基、取代(C1-C12)烷基、(C2-C16)烯基、(C2-C16)炔基、(C3-C10)环烷基、(C6-C10)芳基、单取代或双取代的(C6-C10)芳基、(C6-C10)芳基-(C1-C4)烷基、单取代或双取代的(C6-C10)芳基-(C1-C4)烷基、杂环-(C1-C4)烷基和单取代或双取代的杂环-(C1-C4)烷基。本发明还涉及这些化合物的抗真菌用途和制备方法,以及它们作为药物组成物的制剂。